title: How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.
abstract: Trastuzumab administered in combination with various chemotherapy regimens has led to outstanding improvements in both disease-free survival and overall survival. So far, thousands of patients have been treated in this way which has proven to be reasonably safe, with cardiac events being the predominant recognisable toxicity requiring surveillance. Notwithstanding the large cumulative experience of the oncology community in treating early HER2/neu-positive breast cancer with trastuzumab, some uncertainties remain, with key issues being the ideal time of chemotherapy administration and the optimal duration of trastuzumab therapy. This paper discusses these issues in the light of the recent updates of some of the pivotal clinical trials in the adjuvant context.
authors.affiliation: Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium ; Br.E.A.S.T. Data Centre, Institut Jules Bordet, Brussels, Belgium.
authors.forename: Ana Catarina
authors.initials: AC
authors.lastname: Pinto
authors.affiliation: Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium ; Br.E.A.S.T. Data Centre, Institut Jules Bordet, Brussels, Belgium.
authors.forename: Evandro
authors.initials: E
authors.lastname: de Azambuja
authors.affiliation: Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
authors.forename: Martine
authors.initials: M
authors.lastname: Piccart-Gebhart
keywords: Adjuvant; Early breast cancer; HER2/neu-positive; Trastuzumab